Literature DB >> 8491447

Renal effects of acute isosorbide-5-mononitrate administration in cirrhosis.

J M Salmerón1, L Ruiz del Arbol, A Ginès, J C García-Pagán, P Ginès, F Feu, J Claria, F Rivera, J Bosch, V Arroyo.   

Abstract

The aim of this study was to assess the effects of an oral dose (20 mg) of isosorbide-5-mononitrate on systemic hemodynamics, kidney function, plasma renin activity and plasma aldosterone and atrial natriuretic peptide concentrations in 16 nonazotemic cirrhotic patients. Isosorbide-5-mononitrate significantly reduced cardiopulmonary pressures, cardiac output, peripheral vascular resistance, mean arterial pressure, renal plasma flow, glomerular filtration rate, free water clearance, sodium excretion and atrial natriuretic peptide concentration and significantly increased renin and aldosterone values. Cardiopulmonary pressures, atrial natriuretic peptide, cardiac output and mean arterial pressure decreased to a similar extent in patients with (n = 9) and without ascites (n = 7). In patients with ascites we noted marked increases in plasma renin activity (3.7 +/- 1.1 ng/ml/hr to 6.4 +/- 1.8 ng/ml/hr; p = 0.01) and aldosterone level (61.1 +/- 17.5 ng/dl to 108.4 +/- 36.1 ng/dl; p = 0.01). In contrast, in patients without ascites the elevation of plasma renin activity (0.5 +/- 0.16 ng/ml/hr to 0.95 +/- 0.27 ng/ml/hr; p = 0.02) and aldosterone level (5.9 +/- 1.3 ng/dl to 12.3 +/- 3.8 ng/dl; p = 0.02) was mild, and in no case did these parameters increase over the upper normal limit. Isosorbide-5-mononitrate produced a significantly greater reduction of glomerular filtration rate (-21.4% +/- 3.3% vs. -8.9% +/- 4.2%; p = 0.03) and free water clearance (-82.4% +/- 16.1% vs. -34.5% +/- 12.3%; p = 0.03) in patients with ascites than in those without.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8491447

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  8 in total

1.  Somatostatin plus isosorbide 5-mononitrate versus somatostatin in the control of acute gastro-oesophageal variceal bleeding: a double blind, randomised, placebo controlled clinical trial.

Authors:  F Junquera; J C López-Talavera; F Mearin; E Saperas; S Videla; J R Armengol; R Esteban; J R Malagelada
Journal:  Gut       Date:  2000-01       Impact factor: 23.059

Review 2.  Pathophysiology of portal hypertension and its clinical links.

Authors:  Yeon Seok Seo; Vijay H Shah
Journal:  J Clin Exp Hepatol       Date:  2011-11-09

Review 3.  Serelaxin in clinical development: past, present and future.

Authors:  Elaine Unemori
Journal:  Br J Pharmacol       Date:  2017-01-29       Impact factor: 8.739

4.  Effects of Sapropterin on Portal and Systemic Hemodynamics in Patients With Cirrhosis and Portal Hypertension: A Bicentric Double-Blind Placebo-Controlled Study.

Authors:  Enric Reverter; Francisco Mesonero; Susana Seijo; Javier Martínez; Juan G Abraldes; Beatriz Peñas; Annalisa Berzigotti; Ramon Deulofeu; Jaume Bosch; Agustín Albillos; Joan Carles García-Pagán
Journal:  Am J Gastroenterol       Date:  2015-06-16       Impact factor: 10.864

5.  Acute effect of propranolol and isosorbide-5-mononitrate administration on renal blood flow in cirrhotic patients.

Authors:  A J Stanley; I A Bouchier; P C Hayes
Journal:  Gut       Date:  1998-02       Impact factor: 23.059

Review 6.  Nitric oxide and portal hypertension.

Authors:  Juan González-Abraldes; Juan Carlos García-Pagán; Jaime Bosch
Journal:  Metab Brain Dis       Date:  2002-12       Impact factor: 3.584

7.  A Nitric Oxide-Donating Statin Decreases Portal Pressure with a Better Toxicity Profile than Conventional Statins in Cirrhotic Rats.

Authors:  Sarai Rodríguez; Imma Raurell; Manuel Torres-Arauz; Teresa García-Lezana; Joan Genescà; María Martell
Journal:  Sci Rep       Date:  2017-01-13       Impact factor: 4.379

8.  Serelaxin as a potential treatment for renal dysfunction in cirrhosis: Preclinical evaluation and results of a randomized phase 2 trial.

Authors:  Victoria K Snowdon; Neil J Lachlan; Anna M Hoy; Patrick W F Hadoke; Scott I Semple; Dilip Patel; Will Mungall; Timothy J Kendall; Adrian Thomson; Ross J Lennen; Maurits A Jansen; Carmel M Moran; Antonella Pellicoro; Prakash Ramachandran; Isaac Shaw; Rebecca L Aucott; Thomas Severin; Rajnish Saini; Judy Pak; Denise Yates; Neelesh Dongre; Jeremy S Duffield; David J Webb; John P Iredale; Peter C Hayes; Jonathan A Fallowfield
Journal:  PLoS Med       Date:  2017-02-28       Impact factor: 11.069

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.